280 related articles for article (PubMed ID: 22587010)
1. A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.
Huang ZH; Shi L; Ma JW; Sun ZY; Cai H; Chen YX; Zhao YF; Li YM
J Am Chem Soc; 2012 May; 134(21):8730-3. PubMed ID: 22587010
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
[TBL] [Abstract][Full Text] [Related]
3. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
4. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
5. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
6. First self-adjuvant multicomponent potential vaccine candidates by tethering of four or eight MUC1 antigenic immunodominant PDTRP units on a calixarene platform: synthesis and biological evaluation.
Geraci C; Consoli GM; Granata G; Galante E; Palmigiano A; Pappalardo M; Di Puma SD; Spadaro A
Bioconjug Chem; 2013 Oct; 24(10):1710-20. PubMed ID: 24041198
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
8. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
9. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
[TBL] [Abstract][Full Text] [Related]
10. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
Wilkinson BL; Day S; Malins LR; Apostolopoulos V; Payne RJ
Angew Chem Int Ed Engl; 2011 Feb; 50(7):1635-9. PubMed ID: 21308921
[No Abstract] [Full Text] [Related]
11. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
12. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
[TBL] [Abstract][Full Text] [Related]
13. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen.
Schuman JT; Grinstead JS; Apostolopoulos V; Campbell AP
Biopolymers; 2005 Feb; 77(2):107-20. PubMed ID: 15635690
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
15. Synthetic glycopeptides for the development of cancer vaccines.
Liakatos A; Kunz H
Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
[TBL] [Abstract][Full Text] [Related]
16. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of MUC1 glycopeptide thioesters and ligation via direct aminolysis.
Wilkinson BL; Chun CK; Payne RJ
Biopolymers; 2011; 96(2):137-46. PubMed ID: 20564042
[TBL] [Abstract][Full Text] [Related]
18. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
19. Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines.
Liu Y; Zhang W; He Q; Yu F; Song T; Liu T; Zhang Z; Zhou J; Wang PG; Zhao W
Chem Commun (Camb); 2016 Sep; 52(72):10886-9. PubMed ID: 27530357
[TBL] [Abstract][Full Text] [Related]
20. Synthetic glycopeptides for the development of tumour-selective vaccines.
Kunz H
J Pept Sci; 2003 Sep; 9(9):563-73. PubMed ID: 14552419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
